dermatologyadvisor8d
Long-Term Lebrikizumab in AD Is Effective Despite Inadequate Short-Term Response
Long-term lebrikizumab was effective for atopic dermatitis treatment in patients who did not have adequate response to short-term treatment.
Healio9d
‘Don’t give up’: Long-term lebrikizumab for AD may benefit initial nonresponders
Long-term treatment with lebrikizumab may be beneficial for patients with atopic dermatitis that were not initially ...
pharmaphorum3d
Almirall/Lilly lebrikizumab offers potential long-term management of atopic dermatitis
Lebrikizumab, a monoclonal antibody that inhibits an interleukin named IL-13, is especially promising in treatment of this disease. Having been in development by Almirall and Eli Lilly and Company ...
pharmaphorum5y
Almirall takes option on Dermira's eczema drug lebrikizumab
Spain’s Almirall has taken an option granting rights to develop and market Dermira’s eczema drug lebrikizumab in Europe, in a bid to take on Sanofi/Regeneron's recently approved Dupixent.
Pharmabiz3d
Apogee begins patient dosing in Part B of phase 2 APEX trial of APG777 to treat moderate-to-severe atopic dermatitis
Apogee begins patient dosing in Part B of phase 2 APEX trial of APG777 to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 4, 2025, 18:00 Hrs [IST] Apog ...